First real-world study of COVID-19 Vaccine AstraZeneca demonstrates 94% reduction in hospitalisations

Results from the first study to describe the real world effectiveness of COVID-19 Vaccine AstraZeneca have demonstrated that the vaccine is able to substantially reduce the risk of COVID-19 related hospitalisation by 94% after the first dose. These findings, published on the 22 February 2021 as a pre-print, were based on data from 1.14 million COVID-19 vaccinations administered in Scotland, UK with approximately 490,000 people having received the first dose of the AstraZeneca vaccine.

The majority of those in the study who received COVID-19 Vaccine AstraZeneca were over 80 years old, and the effects of the vaccine were seen to be comparable across all age groups. This data provides further evidence that the vaccine protects against severe COVID-19 outcomes, particularly in older populations who are at the highest risk.

 

These data are extremely encouraging as they confirm the effectiveness of our vaccine in a real world setting against severe COVID-19 outcomes. We are deeply committed to ensuring broad and equitable access of our vaccine globally to help overcome the challenges of this pandemic, as quickly as possible.

Mene Pangalos EVP, BioPharmaceuticals R&D

This first national population level study, led by the University of Edinburgh together with Public Health Scotland, assessed the effect of currently licensed COVID-19 vaccines on a serious COVID-19 outcome in 5.4 million people in Scotland, UK, including adults aged 65 years and older. Vaccine effect of COVID-19 Vaccine AstraZeneca was highest at 28-34 days post-first vaccination.

AstraZeneca will continue to work with regulators in the UK and around the world to build our knowledge of the real world effectiveness of the vaccine, across diverse populations. This is in addition to our ongoing clinical trial programme which is providing data from up to 60,000 participants globally.

With health systems around the world struggling to cope with the burden of hospital and critical care admissions resulting from COVID-19, the ability of vaccines to be effective in reducing hospitalisation in a real world setting is of critical importance.


Veeva ID: Z4-31099
Date of Preparation: February 2021